































































Molecular characterization of equine
thymidine kinase 1 and preliminary
evaluation of its suitability as a serum
biomarker for equine lymphoma
Liya Wang1*, Lucia Unger2, Hanan Sharif1,3, Staffan Eriksson1, Vinzenz Gerber2 and Henrik Rönnberg4
Abstract
Background: Thymidine kinase 1 (TK1) plays a key role in the synthesis of deoxythymidine triphosphate (dTTP) and
is thus important for DNA replication and cell proliferation. The expression of TK1 is highest during S-phase, and it
is rapidly degraded after mitosis. In cancer cells, TK1 is upregulated, resulting in leakage of excess TK1 into the
blood. Consequently, serum TK1 has been used as a diagnostic and prognostic cancer biomarker, mainly in human
medicine. The aims of this work were to characterize equine TK1 and to evaluate its suitability as a serum biomarker
for equine lymphoma.
Results: Equine TK1 was cloned, expressed in E. coli and affinity purified. The purified recombinant horse TK1
showed broad substrate specificity, phosphorylating pyrimidine deoxyribo- and ribonucleosides and, to some
extent, purine deoxynucleosides, including anticancer and antiviral nucleoside analogues. ATP was the preferred
phosphate donor. Serum TK1 activity was measured in samples collected from horses with confirmed or suspected
lymphoma and control horses with and without concurrent diseases. Serum TK1 activity levels were significantly
higher in horses with lymphoma (p < 0.0005) and suspected lymphoma (p < 0.02) and in tumour-free groups with
diverse diseases (p < 0.03) than in controls without concurrent diseases. There was a significant difference between
the lymphoma group and the tumour-free group with diverse diseases (p < 0.0006). Furthermore, receiver
operating characteristic analysis revealed a sensitivity of 0.86, a specificity of 0.95 and an AUC (area under the curve)
of 0.92 compared to the controls without concurrent diseases, with a sensitivity of 0.97, a specificity of 0.71 and an
AUC of 0.88 when compared with the tumour-free group with diverse diseases.
Conclusion: Equine TK1 showed high specific activity and broader substrate specificity than human TK1. Anticancer
and antiviral thymidine analogues were efficiently phosphorylated by horse TK1, suggesting that these analogues
might be good candidates for chemotherapy in horses. Serum TK1 activity was significantly higher in horses with
lymphoma than in controls. ROC analysis indicated that serum TK1 could serve as a promising cancer biomarker in
horses.
Keywords: Equine thymidine kinase 1, cancer, Serum biomarker, Equine lymphoma, Nucleoside analogues, Enzyme
kinetics
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Background
Like any other animals, horses can develop cancers. A
recent survey of equine tumours in the United King-
dom found lymphoma to be the third most commonly
diagnosed tumour after equine sarcoid and squamous
cell carcinoma [1]. Lymphoma, although rare in the
total equine population, is the most common haemato-
poietic neoplasm encountered in horses and can occur
in horses of any age, with horses at 4–10 years most
commonly affected [2]. There are five general types of
lymphoma: multicentric, alimentary, mediastinal, cuta-
neous and solitary lymphoma. Multicentric lymphoma
is the most common equine lymphoma type and shows
a vast range of clinical presentations depending on
which organs are affected. Alimentary lymphoma most
frequently involves the small intestines, followed by the
ascending and small colon, and causes malabsorption,
which leads to severe weight loss, diarrhoea and some-
times colic [3]. Mediastinal lymphoma is characterized
by neoplastic infiltration of the lymph nodes in the
thoracic cavity causing compression of structures in the
cranial mediastinum and thus leading to coughing, dys-
pnoea, distended jugular veins and muffled heart
sounds secondary to thoracic effusion. Cutaneous
lymphoma presents with multifocal, cutaneous nodules
without internal metastasis, and solitary lymphomas
may affect any organ, such as the spleen, or anatomical
structures of the equine skull, such as the nasal pas-
sages or sinuses. Equine lymphoma is further classified
according to its immunophenotype as of either B- or T-
cell origin [2, 4, 5].
Clinical signs of cancer are generally vague and unspe-
cific in horses and most commonly include apathy,
weight loss, exercise intolerance and fever. In such cases,
a systemic neoplastic disease should be considered as a
differential diagnosis when more common causes, such
as infectious diseases, severe parasite burden or dental
or digestive disorders, have been ruled out, or if horses
do not respond to standard therapy and show progres-
sive loss of function of one or more organ systems [6].
Haematological and biochemical profile changes are also
nonspecific and most importantly include anaemia, neu-
trophilia, hyperfibrinogenaemia, hypoalbuminemia and
hyperglobulinemia [2]. Further diagnostic work-up may
be quite extensive and invasive and often requires the
expertise of a veterinary specialist. Depending on clinical
signs, this work-up can include a rectal exam, abdominal
and thoracic ultrasound, thoracic radiographs, abdo-
mino- and thoracocentesis and fine needle aspirates or
biopsies from internal organs collected with ultrasound
guidance or during explorative laparotomy. The lack of
reliable and noninvasive equine cancer biomarkers re-
sults in delayed diagnosis, ineffective treatment options
and poor overall survival.
Deoxythymidine triphosphate (dTTP), one of the es-
sential building blocks of DNA, is synthesized by two
distinct pathways, e.g., the de novo pathway and the sal-
vage pathway. In the salvage pathway, the synthesis of
dTTP starts with the phosphorylation of thymidine cata-
lysed by thymidine kinases, which is the rate-limiting
step. Two thymidine kinases exist in mammalian cells:
cytosolic thymidine kinase 1 (TK1) and mitochondrial
thymidine kinase 2 (TK2). The expression of TK1 is cell
cycle-specific, with its highest expression level during S-
phase of the cell cycle [7], while the highest expression
levels of TK2 are in the stationary phase [8]. The level of
TK1 declines drastically after mitosis via a ubiquitin-
proteasome regulated pathway [9]. In cancer cells, the
cell cycle-regulated expression of TK1 is disrupted,
resulting in overexpression and leakage of TK1 into the
blood. Therefore, serum TK1 has been used in health
screening to detect premalignant diseases and as a diag-
nostic and prognostic biomarker for cancer in human
medicine [10, 11]. In veterinary medicine, serum TK1
has also been evaluated as a biomarker for diagnosis and
prognosis, primarily in dogs with haematopoietic malig-
nancies [12–14] but also in horses with lymphoma, with
a sensitivity of 74% and a specificity of 86% and an AUC
(are under the curve) of 0.80 as a diagnostic biomarker
for this disease [15].
Pyrimidine nucleoside analogues such as AZT (azido-
thymidine) and 5FdU (5-fluoro-2′-deoxyuridine) have
been used as chemotherapeutics for viral infection and
cancer for more than 50 years. The activation of these
nucleoside analogues by TK1 is a prerequisite for their
antiviral and anticancer activity. In equine medicine, nu-
cleoside analogues have been used for the treatment of
viral infection and lymphoma [16–18]. However, equine
TK1 has not yet been characterized; therefore, its role in
the activation of therapeutic nucleosides is unknown.
The aims of this study were to characterize equine
TK1 and to evaluate its serum level as a biomarker for
equine lymphoma. Equine TK1 cDNA was identified
and cloned into the pET-14b vector for expression in E.
coli, and recombinant horse TK1 was affinity purified
and characterized. Serum samples from healthy and dis-
eased horses were collected, and the levels of TK1 were
determined.
Results
Molecular characterization of equine TK1
Equine TK1 sequence analysis
The horse TK1 gene (tk1) is approximately 12.6 kb long
and is located on chromosome 11. At the mRNA level,
there were four alternatively spliced transcripts found in
the database, encoding proteins varying from 211 to 283
amino acids in length. However, which of the four tran-
scripts is dominant is currently unknown. As shown in
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Fig. 1 A Amino acid sequence alignment of equine TK1 isoforms with human TK1 using the Clustal Omega algorithm (https://www.ebi.ac.uk/
Tools/msa/clustalo/) and structural alignment using ENDscript 2.0 software (http://endscript.ibcp.fr/ESPript/cgi-bin/ENDscript.cgi) with the human
TK1 structure as the template. B Predicted 3D structure for isoform 1. C Predicted 3D structure for isoform 3. D Superimposed structures of
isoforms 1 and 3. Structure prediction was performed with fully automated structural modelling software (https://sissmodel.expasy.org) using the
human TK1 structure in complex with dTTP as a template (PDB code: 1W4R)
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Fig. 1A, isoform 4 is the shortest transcript, and the pre-
dicted protein sequence lacks the ATP-binding loop (p-
loop); thus, it is presumably nonfunctional. In isoforms
1, 2, and 3, all important functional motifs, e.g., the p-
loop, the Zn-binding motif and the “KEN” motif, are
present (Fig. 1A). However, an insertion of amino acid
residues 46 (isoforms 1 and 4) and 22 (isoform 2) exists
between α-helices η2 and α3 (Fig. 1A), which may form
a large loop structure, as predicted based on the proper-
ties of the inserted amino acid sequence for isoform 1
(Fig. 1B) when compared with isoform 3 (Fig. 1C and D)
using Swiss-Model, a fully automated protein structure
homology server with the human TK1 structure in
complex with dTTP as a template (PDB code: 1W4R).
The formation of this loop structure may result in an in-
active enzyme, since α-helices η2 and α3 play an import-
ant role in the formation of the active site structure,
although in the predicted 3D structure of isoform 1, the
loop structures are outside the core structure (Fig. 1B and
D). Isoform 3 is the only transcript that codes for a poly-
peptide with primary and tertiary structures that are simi-
lar to those of human TK1 (Fig. 1A and C) and thus is
considered the functional horse TK1. Horse TK1 (isoform
3) consists of 237 amino acids with a calculated molecular
weight of 27.94 kDa and shows > 95% sequence homology
to TK1 proteins in other species [19, 20].
To characterize the horse enzyme, isoform 3 cDNA
was cloned into the pET-14b expression vector, and the
recombinant horse TK1 protein was expressed in E. coli
as a fusion protein with an N-terminal 6 X histidine tag
to facilitate purification. The recombinant horse TK1
protein was then affinity purified to more than 95%
purity by using Ni2+-Sepharose column chromatography
(Fig. 2A). The yield of pure TK1 was ~ 2mg per litre of
culture. The identity of the purified recombinant horse
TK1 was confirmed by western blot analyses using two
specific antibodies, one recognizes specifically the
6xHistidine-tag (Fig. 2B) and one recognizes only the
TK1 protein (Fig. 2C).
Substrate specificity
TK1 catalyses the transfer of a gamma phosphate group
from a nucleoside triphosphate (phosphate donor) to the
5′-OH group of a nucleoside (phosphate acceptor),
resulting in the formation of nucleoside 5′-monopho-
sphate. Therefore, both phosphate acceptor and phos-
phate donor specificities were studied. Using ATP as the
phosphate donor, a number of pyrimidine and purine
nucleosides and some of their analogues were tested
using a coupled spectrophotometric method. At a con-
centration of 100 μM, the activities of all the tested nu-
cleosides were compared with that of thymidine (dThd,
set to 100%). As shown in Table 1, among all the dThd
analogues tested, TFT (trifluorothymidine) had higher
activity, but AZT, FLT (fluorothymidine), and D4T
(stavudine) showed lower relative activity than dThd. No
activity was detected with α-dThd. Surprisingly, dUrd
and its analogue 5FdU showed higher relative activity
than dThd, while other tested dUrd analogues, e.g., L-
and D-FMAU, FMAU, and FIAU, showed lower relative
activity. Uridine (Urd) showed some activity, but not
dCyd, cytidine, dGuo or dAdo (Table 1). These results
demonstrated that horse TK1 has a broader substrate
specificity than human TK1 [21].
Fig. 2 Characterization of recombinant horse TK1. SDS-PAGE analysis A and western blot analyses of recombinant horse TK1 with antibodies
against 6xHistidine-tag B and TK1 C. Lane 1, E. coli extracts of uninduced culture; lane 2, E. coli extracts of induced culture; lane 3, purified
recombinant horse TK1
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Phosphate donor specificity was studied with
100 μM [3H]-dThd as the phosphate acceptor using a
radiochemical assay. All natural nucleoside triphos-
phates at a 1 mM concentration could serve as phos-
phate donors, although dTTP only showed 0.1%
relative activity. ATP showed the highest activity,
while dATP showed ~ 71% relative activity, and
other nucleoside triphosphates had ~ 12–24% relative
activity compared with ATP (Table 2). Thus, as
expected, the horse enzyme favours ATP as the
phosphate donor.
Steady-state kinetics
Steady-state kinetic analysis was performed using a
coupled spectrophotometric method. As shown in
Fig. 3A, the phosphorylation of dThd showed negative
cooperativity with a Hill coefficient of 0.57 (Table 3).
The values of the kinetic parameters KM and Vmax were
0.47 μM and 0.95 μmol/min/mg, respectively (Table 3).
However, the phosphorylation of dUrd followed
Michaelis-Menten kinetics (Fig. 3B), with KM and Vmax
values of 1.64 μM and 0.81 μmol/min/mg, respectively.
Due to the higher KM value, the efficiency of dUrd phos-
phorylation was only 25% of that of dThd (Table 3).
The kinetic parameters of selected antiviral and anti-
cancer nucleoside analogues were also determined. The
phosphorylation of 5FdU, TFT and AZT followed
Michaelis-Menten kinetics, and the KM values were 1.06
(5FdU) μM, 0.72 (TFT) μM, and 0.12 (AZT) μM, re-
spectively, which are in the same range as dThd. How-
ever, the Vmax values for these analogues varied; thus,
their efficiencies were lower than that of dThd except
for AZT, which had higher efficiency than dThd (Table
3). These findings are different from those for human
and dog TK1 [20, 21].
The phosphorylation of Urd and dGuo was also inves-
tigated using a wider concentration range. As shown in
Fig. 3C, Urd phosphorylation followed Michaelis-
Menten kinetics with a KM value of 1511 μM and a Vmax
value of 0.41 μmol/min/mg (Table 3), while the phos-
phorylation of dGuo did not reach the Vmax value even
at the highest concentration that could be achieved
under these assay conditions; therefore, no kinetic pa-
rameters were calculated (Fig. 3D).
The kinetics of ATP showed positive cooperativity
with a Hill coefficient of 1.9 (Fig. 4). The KM and Vmax
values for ATP were 1501 μM and 3.00 μmol/min/mg,
respectively (Table 3). These results suggest that the
binding of ATP may affect subunit interactions, as ob-
served in human TK1 [22].
Serum sample collection and serum TK1 analysis
Serum samples (including 1 plasma sample) were col-
lected from 7 horses with confirmed lymphoma, 5
horses with suspected lymphoma, 107 control horses
with concurrent diseases and 42 horses without concur-
rent diseases (detailed clinical information is provided in
Supplementary Table 1). TK1 activity in serum samples
was determined using [3H]-dThd as the substrate, a
method developed previously for dog serum TK1 mea-
surements and shown here to also work well for horse
serum TK1 activity determinations [23]. The mean value
and standard deviation and the median and range in






















The assay was performed using a coupled spectrophotometric method at
21 °C. The substrate concentration was 0.1 mM with 1mM ATP as the
phosphate donor. The data are given as a percentage of that with
dThd (0.95 μmol/mg/min)
Table 2 Phosphate donor specificity









The assay was performed by using a radiochemical assay with [3H]-dThd as
the substrate at 37 °C. The concentration of dThd was 0.1 mM, and the
phosphate donor concentration was 1 mM. The data are given as a percentage
of that with ATP as a phosphate donor (0.47 μmol/mg/min)
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each group are shown in Table 4. The mean serum TK1
activity of the control group without concurrent diseases
was 0.33 pmol/min/ml with a standard deviation (SD) of
0.16 pmol/min/ml; thus, we could deduce a tentative
cut-off value of 0.65 pmol/min/ml (mean + 2xSD). In the
tumour-free control group with concurrent diseases,
there were 5 out of 107 horses with serum TK1 activity
above the cut-off value, and in the confirmed and
suspected lymphoma groups, there was 1 horse in each
group with serum TK1 activity below the cut-off value
(Supplementary Table 1). As shown in Fig. 5A, the
serum TK1 activity was significantly higher in the
lymphoma (p < 0.0005), suspected lymphoma (p < 0.02)
and tumour-free with concurrent diseases (p < 0.03)
groups than in the controls without concurrent diseases,
and there was a significant difference between the
Fig. 3 Steady-state kinetic analysis of horse TK1. Plots of initial velocity versus substrate concentration, dThd A, dUrd B, Urd C and dGuo D. The
ATP concentration was kept at 1 mM
Table 3 Kinetic parameters of horse TK1
Substrate KM (μM) Vmax (μmol/min/mg) Efficiency (Vmax/KM) Hill coefficient
dThd 0.47 ± 0.09 0.95 ± 0.02 2.02 (100)a 0.57
dUrd 1.64 ± 0.50 0.81 ± 0.05 0.49 (25.0) 1.0
5FdU 1.06 ± 0.2 1.08 ± 0.05 1.02 (50.4) 1.0
AZT 0.12 ± 0.08 0.53 ± 0.02 4.56 (225.9) 1.0
TFT 0.72 ± 0.28 0.93 ± 0.02 1.29 (64.0) 1.0
Urd 1511 ± 229 0.41 ± 0.02 0.00027 (0.013) 1.0
ATP 1501 ± 287 3.00 ± 0.29 0.0020 1.9
Kinetic parameters were determined using a coupled spectrophotometric method at 21 °C. To determine the kinetic parameters for phosphate acceptors, the ATP
concentration was fixed at 1 mM, and to determine the kinetic parameters for ATP, the dThd concentration was fixed at 100 μM. The KM and Vmax values were
calculated by fitting the initial velocity data into the Michaelis-Menten equation. The Hill coefficient was calculated by fitting the initial velocity data into the
Hill equation
aData in parentheses are relative efficiency compared with dThd (as 100%)
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lymphoma group and the tumour-free group with con-
current diseases (p < 0.0006).
ROC (receiver operating characteristic) analysis was
conducted to evaluate the utility of serum TK1 as a
biomarker and revealed a sensitivity of 0.86, a specifi-
city of 0.95 and an AUC (area under the curve) of
0.92 for the confirmed lymphoma group using a cut-
off of ≤0.65 pmol/min/ml. At the 95% confidence
interval (CI), the AUC was 0.77–1.07 with a p value
of 0.00045 when compared with the control group
without concurrent diseases (Fig. 5B). For the non-
neoplastic disease group (nontumour diseases), ROC
analysis resulted in a sensitivity of 0.06, a specificity
of 0.95 and an AUC of 0.62 using a cut-off value of
0.65 (Fig. 5C). ROC analysis of the lymphoma group
against the nontumour disease group showed a speci-
ficity of 0.71, a sensitivity of 0.97 and an AUC of
0.88 using a cut-off of 1.0 pmol/min/ml, and at the
95% CI, the AUC was 0.7–1.1 with a p value of
0.0006 (Fig. 5D). These results demonstrated that
serum TK1 could serve as a useful biomarker to dis-
tinguish individuals with lymphoma from control
horses with and without concurrent diseases.
Discussion
TK1 plays an important role in cellular dTTP synthe-
sis, and its expression is closely correlated with DNA
replication and cell proliferation. TK1 expression is
also a prerequisite for the activation of certain thymi-
dine analogues used in chemotherapy and as a diag-
nostic and prognostic biomarker for neoplastic
disease. Therefore, it is necessary to characterize the
molecular properties of equine TK1 enzyme in nor-
mal and neoplastic conditions to understand its po-
tential role in veterinary medicine. In this study, we
cloned, expressed and characterized equine TK1. Our
results showed that horse TK1 preferred thymine and
uracil as the base moieties of its substrate since dCyd,
cytidine, dGuo and dAdo did not show any detectable
activity under the same conditions. Modifications at
the 5′-position of the thymine or uracil base resulted
in higher activity. As expected, the enzyme preferred
deoxyribose as its sugar moiety, as shown in Table 1.
Urd had much lower activity than its corresponding
deoxyribonucleoside, dUrd. Furthermore, modifica-
tions of the sugar moiety resulted in significantly de-
creased activity.
Fig. 4 Steady-state kinetic analysis of horse TK1. ATP was the variable substrate, and the dThd concentration was kept at 0.1 mM
Table 4 Analysis of serum TK1 activity (pmol/min/ml)a
Mean Standard deviation Median Range
Controls (n = 40) 0.33 0.16 0.29 0.10–0.82
Confirmed lymphoma (n = 7) 4.7 6.1 2.5 0.28–17.7
Suspected lymphoma (n = 5) 3.3 2.2 3.2 0.18–6.5
Nontumour diseases (n = 107) 0.40 0.30 0.36 0.11–2.96
aControls = horses without concurrent diseases (clinically healthy horses). Nontumour diseases = tumour-free horses with diverse concurrent diseases
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Horse TK1 is stringent regarding the configuration of
its base since α-dThd showed no detectable activity,
while the β-configuration (natural dThd) had 100% ac-
tivity. The configuration of the sugar moiety also played
a role in substrate selectivity since D-FMAU had 3 times
the activity of L-FMAU and the activity of the racemic
mixture FMAU was the average of those of the D- and
L-form (Table 1). These results are consistent with what
has been observed for human TK1 [24].
The results revealed that horse TK1 phosphorylated its
natural substrate dThd with high efficiency, but the en-
zyme exhibited a somewhat broader substrate specificity
than TK1 from humans and dogs [20, 21]. The kinetic
behaviour of horse TK1 differed from those of human
and dog TK1 in that all tested substrates followed
Michaelis-Menten kinetics except dThd, which demon-
strated negative cooperativity [20, 21]. The anti-HIV
nucleoside analogue AZT showed higher efficiency than
that of dThd due to its low KM value. The anticancer
nucleoside analogues 5FdU and TFT had > 50% relative
efficiency compared with dThd. These results suggest
that these analogues can be efficiently phosphorylated by
horse TK1 and thus support further investigations of
their potential use in antiviral and anticancer therapies.
Nucleoside analogues are widely used in antiviral and
anticancer therapies; currently, > 50% of antiviral and
anticancer drugs are nucleobases, nucleosides and nu-
cleotide analogues. Nucleoside analogues are prodrugs
that need to be activated by cellular nucleoside kinases
to exert their therapeutic potential. The nucleoside ana-
logues tested in this study, AZT, TFT, and 5FdU, are ac-
tivated by TK1 and used for the treatment of HIV,
herpes simplex virus type 1 and 2 and vaccinia virus in-
fection or cancers in humans. This is of particular
Fig. 5 Analysis of serum TK1 levels. A. Comparison of serum TK1 levels in the control group without concurrent disease (Controls, n = 40), the
lymphoma (n = 7) and suspected lymphoma (n = 5) groups and the tumour-free group with concurrent diseases (nonneoplastic diseases, n =
107). Bars represent the median. Receiver operating characteristic (ROC) analysis of serum TK1 activity to distinguish horses with lymphoma B and
nonneoplastic diseases (nontumour diseases) C from the control group without concurrent diseases. The sensitivity and specificity were
determined based on the chosen cut-off of 0.65 pmol/min/ml. To distinguish lymphoma from nonneoplastic diseases (nontumour disease group)
D, the sensitivity and specificity were determined at a chosen cut-off value of 1.0 pmol/min/ml (mean + 2 SD)
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interest for the development of new treatment strategies
for equine lymphoma, which has been recently associ-
ated with EHV-5 infection [25]. Nucleoside analogues
such as cytosine arabinoside, acyclovir and valacyclovir
have already been used as chemotherapeutic agents in
horses with lymphoma. Both acyclovir and valacyclovir
were associated with complete or partial remission in se-
lected cases of EHV-5-associated lymphoma [17, 26, 27].
Although the antiviral and anticancer nucleoside ana-
logues tested here have not yet been used in clinical set-
tings in equine practice to date, the results presented
here suggest that they may be good candidates for the
treatment of cancers, viral infections or a combination
of both in horses.
Biomarkers are molecules that can be objectively and
easily measured and evaluated as indicators of normal and
pathogenic processes and can be used in medical screen-
ing, diagnosis and treatment monitoring [28]. Serum TK1
activity has been used as a biomarker for health screening
to detect premalignant diseases and for cancer diagnosis
and prognosis in human medicine [11, 29]. In veterinary
medicine, serum TK1 has also been shown to be a useful
biomarker to diagnose malignant diseases in dogs and to
monitor treatment [12–14, 20, 30]. Since equine lymph-
oma is a disease with many faces and usually unspecific
symptoms, a reliable blood-based biomarker such as TK1
would greatly assist in the noninvasive identification of
horses with lymphoma in not only advanced but also early
stages of cancer. Indeed, in this study, we were able to
show that the serum TK1 activity in horses with con-
firmed lymphoma was significantly higher than the activ-
ities in control horses with and without concurrent
diseases. These results are in accordance with what was
reported previously using a radioenzymatic technique
(TK-REA assay) [15], but our assay method showed higher
diagnostic sensitivity and specificity and a significantly
higher AUC value upon ROC analysis. The test presented
here was also superior to tests relying on serum IgM con-
centrations, which have a very poor sensitivity (23%) but a
satisfactory specificity (88%) for diagnosing equine lymph-
oma at a cut-off of ≤23mg/dl.
Our study cohort consisted of a relatively large and di-
verse group of control horses, including a population of
old, well-monitored horses owned by a foundation, and
thus offered a particularly adequate and reliable control
group. As stated above, even though lymphoma is one of
the more common forms of neoplasia in horses, in the
general equine population it is nevertheless a rare condi-
tion limiting the number of confirmed cases referred to
the ISME equine clinic throughout the sampling period
to only seven. This might have decreased the statistical
power and is the main limitation of this study. Addition-
ally, we included a small cohort of horses with clinical
signs highly suggestive of lymphoma, for which
measurement of TK1 activity further corroborated this
presumptive diagnosis. This shows that TK1 activity
may be used as a diagnostic biomarker in daily equine
practice when a more elaborate and invasive workup is
denied by the horse owner.
The prognosis of lymphoma depends on the type and
extent of metastasis; cutaneous lymphoma progresses
slowly, and the affected horses may survive for several
years with little or no treatment if no internal metastases
occur. In contrast, for other types of lymphoma, such as
generalized, alimentary or mediastinal lymphoma, the
prognosis is poor, particularly if the disease is diagnosed
at advanced stages. Therefore, early diagnosis is vital for
the success of treatment and thus overall survival. Future
studies evaluating serum TK1 as a diagnostic and prog-
nostic biomarker for equine neoplastic conditions in lar-
ger study cohorts are warranted.
Conclusion
Horse TK1 showed broader substrate specificity than
TK1 from some other species, phosphorylating not only
pyrimidine deoxyribonucleosides but also pyrimidine ri-
bonucleosides and, to some extent, purine deoxynucleo-
sides, including anticancer and antiviral nucleoside
analogues. This information serves as a starting point for
the understanding of the basic molecular biology of
horse TK1 and its diagnostic and therapeutic uses in
equine oncology.
The serum TK1 activity level in horses with malignant
diseases was significantly higher than those of healthy
horses and of horses with concurrent diseases, and there
was no significant difference between the healthy and
disease groups. These results suggest that serum TK1
can be a valuable biomarker to differentiate malignant
from nonneoplastic diseases in horses.
Material and methods
Expression and purification of horse TK1
The horse TK1 gene was identified in the equine gen-
ome database, and cDNA encoding the horse TK1 pro-
tein was synthesized and cloned into the pET-14b vector
(Genscript Inc.). The recombinant horse TK1 contains a
6X histidine tag and a thrombin cleavage site that are
fused to the N-terminus of the horse TK1 sequence.
Plasmid DNA containing horse TK1 cDNA was then
transformed into the E. coli BL21 (DE3) pLysS strain,
which was cultured in LB medium containing the appro-
priate antibiotics. The expression of the recombinant
protein was induced by the addition of 0.1 mM IPTG to
the culture medium, and recombinant horse TK1 was
purified essentially as previously described [31]. Glycerol
(10%) and dithiothreitol (DTT, 5 mM) were added to the
final TK1 preparation, which was stored at − 70 °C in ali-
quots until further analysis. The purified horse TK1 was
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analysed by SDS-PAGE, and the protein concentration
was determined using a Bio-Rad protein assay with bo-
vine serum albumin as the standard.
Western blot analysis
Aliquots of the E. coli cultures before and after induction
with IPTG were centrifuged and the resulting pellets
were resuspended in SDS-sample buffer and heated at
95 °C for 3 min to extract total proteins. These samples
were then separated on 12% polyacrylamide gel together
with the purified recombinant horse TK1. After electro-
phoresis the proteins were transferred to nitrocellulose
membranes by semidry method. One membrane was
probed with anti-6xHis antibody (GE-Healthcare) and
the other was probed with anti-TK1 antibody (Alertix
Veterinary Diagnostics, AB). The signals were detected
by enhanced chemiluminescence (ECL) method (GE
Healthcare) using Image studio system (Bio-Rad).
TK1 activity determination and steady-state kinetics
Stock solutions of nucleosides and nucleoside analogues
were prepared in DMSO and diluted in distilled water
before use. The highest DMSO concentration in the re-
action was 10%, which did not interfere with the TK1
activity measurement when tested with dThd as the
substrate.
The initial velocities of the TK1-catalysed reaction
with different substrates were determined using a
coupled spectrophotometric method [32, 33]. Briefly, the
reaction mixture contained 10mM Tris/HCl, pH 7.6, 5
mM DTT, 5mM MgCl2, 0.5 mM phosphoenolpyruvate,
0.1 mM NADH, 4 u/ml pyruvate kinase, 4 u/ml lactate
dehydrogenase, 1 mM ATP, and variable concentrations
of different substrates in a total of 0.5 ml. The reaction
was started by the addition of purified horse TK1
(12 μg/ml), and the reduction in NADH concentration
was monitored at 340 nm over time. The rate of product
formation was equal to the rate of NADH oxidation in
the reaction. All assays were repeated 3–6 times, and the
results are given as the mean ± SD. The kinetic parame-
ters were calculated by fitting the initial velocity data
into the Michaelis-Menten equation, V0 = Vmax [S]/
(KM+[S]), or the Hill equation, V0 = Vmax [S]
n/(S1/2 +
[S]n), where n is the Hill coefficient, and S1/2 is the sub-
strate concentration required to reach ½ Vmax.
Serum sample collection
Serum samples from horses with histologically con-
firmed lymphoma and suspected lymphoma were col-
lected. The inclusion criteria for horses with suspected
lymphoma were unexplained weight loss in combination
with at least one further abnormal examination findings
suggestive of lymphoma (abdominal and/or thoracic ef-
fusion, disturbance of anatomic function and structure
of one or multiple organs, hypoalbuminemia, hyperfibri-
nogenemia, etc.) after exclusion of more common differ-
ential diagnoses such as infectious diseases, severe
parasite burden or dental or digestive disorders. Further-
more, serum samples from control horses with or with-
out concurrent diseases were collected in the population
of horses referred to or owned by the ISME (Swiss Insti-
tute of Equine Medicine), University of Bern,
Switzerland, and in a population of retired horses owned
by a foundation in Switzerland. Horses were included as
controls if they did not show clinical signs suggestive of
a generalized, malignant internal neoplastic disease.
Horses with PPID (pituitary pars intermedia dysfunc-
tion), also per se representing a neoplastic disease, were
included since pituitary adenomas are considered benign
and the prevalence of PPID is high in old horses [34].
Control horses were further categorized into two groups:
control horses with and without concurrent diseases.
Detail information of all control horses and horses with
confirmed or suspected lymphoma is provided in supple-
mentary Table 1. This project was approved by the Ani-
mal Experimentation Committees of the Cantons of
Bern (BE110/15 and BE41/19+) and Jura (JU EXPE01/
14+), Switzerland. All samples were collected with in-
formed owner consent. All experiments were conducted
in accordance with the ARRIVE guidelines (https:/
arriveguidelines.org) and regulations presented by the
Swedish Animal Protection Ethical Committee.
Serum TK1 activity measurement
The TK1 activity in serum samples was determined
using [3H]-dThd (PerkinElmer) as the substrate essen-
tially as described [23]. Briefly, the reaction mixture con-
taining 10mM Tris–HCl pH 7.6, 2 mM DTT, 5 mM
MgCl2, 5 mM NaF, 5 mM ATP, 5 μM [
3H]-dThd, 10
mM NH4Cl and an appropriate amount of serum in a
total volume of 40 μL was incubated at 37 °C for 60 min.
Aliquots of the reaction mixture were spotted onto
DEAE filter paper (DEAE filtermat, PerkinElmer) and
dried. The filters were then washed 2 times in 1 mM am-
monium formate. Thereafter, the filters were sorted,
eluted in 0.5 ml buffer (0.1 M HCl and 0.2M KCl) and
counted in a scintillation counter (Tri-carb, PerkinEl-
mer) after the addition of scintillation fluid (OptiSafe,
PerkinElmer). All samples were assayed at least 3 times,
and the results are presented as the mean ± SD.
Statistical analysis
The distributions of serum TK1 activity levels in healthy
and diseased groups were evaluated for normality using
the D’Agostino and Pearson omnibus normality test.
The serum TK1 activity levels showed non-Gaussian dis-
tributions, and the Mann-Whitney U test was used for
comparisons between groups. Receiver operating
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characteristic (ROC) curves were constructed to evaluate
the performance of horse serum TK1 activity. All statis-
tical analyses were performed using GraphPad Prism 5.0
(GraphPad Software, La Jolla, CA, USA). Both ROC
curves and median survival were calculated with the
Kaplan-Meier curve using MedCalc version 17.6 (Med-
Calc software, Ostend, Belgium) statistical discovery
software. A P-value < 0.05 was considered significant.
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cause the other half is not relevant.
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